Cargando…
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
Model-informed precision dosing (MIPD) may be a solution to therapeutic failure of infliximab for patients with ulcerative colitis (UC), as underexposure could be avoided, and the probability of endoscopic improvement (pEI; Mayo endoscopic subscore ≤ 1) could be optimized. To investigate in silico w...
Autores principales: | Faelens, Ruben, Wang, Zhigang, Bouillon, Thomas, Declerck, Paul, Ferrante, Marc, Vermeire, Séverine, Dreesen, Erwin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537637/ https://www.ncbi.nlm.nih.gov/pubmed/34683916 http://dx.doi.org/10.3390/pharmaceutics13101623 |
Ejemplares similares
-
Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007) -
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
por: Kantasiripitak, Wannee, et al.
Publicado: (2022) -
Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008) -
Predicting model‐informed precision dosing: A test‐case in tacrolimus dose adaptation for kidney transplant recipients
por: Faelens, Ruben, et al.
Publicado: (2022) -
Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis
por: Hassan, Elham A., et al.
Publicado: (2017)